Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Chart Review of Real-world Treatment Outcomes in Patients With Locally Advanced Unresectable or Metastatic Urothelial Cancer Based on HER2 Expression

NCT05902494 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT05902494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05902494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Chart Review of Real-world Treatment Outcomes in Patients With Locally Advanced Unresectable or Metastatic Urothelial Cancer Based on HER2 Expression
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Observational
Overall status
Completed
Start date
June 29, 2023
Completion date
June 18, 2025
Enrollment
389 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma